Mozobil for Autologous Hematopoietic Stem Cell Transplantation
Phase 2
100
about 2.7 years
18+
1 site in PA
What this study is about
Researchers are testing whether using G-CSF alone, with selective use of Plerixafor, can achieve adequate stem cell collection while possibly reducing the incidence of engraftment syndrome. This treatment is being used in adults who have lymphoma or multiple myeloma and are undergoing autologous stem cell transplantation. The trial will last for about 988 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Gcsf
- 2.Take Plerixafor
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
colony stimulating factor, plerixafor
injection, subcutaneous
Secondary: Cytokine Analysis, Disease Response, Length of Hospital Stay
Oncology